In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes through) become one company, combining Recursion’s expertise in biology with Exscientia’s focus on chemistry.
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
In this week’s InnovationRx newsletter, tariffs could hit medical devices, a gene therapy company that helps blind kids see again, Stand Up for Science rallies, AbbVie gets into weight loss, and ...
After hours: March 21 at 7:59:17 PM EDT Loading Chart for RXRX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback